Chong Kun Dang Pharm Co (185750) · Other

Hanmi Pharm Co Ltd (128940) · Other

Annual general shareholder meeting on 2026-03-31 to vote on the appointment of a new CEO and board members amid a management dispute; high impact estimated due to potential governance shift scheduled.

3/31/2026, 12:00:00 AM

LigaChem Biosciences Inc (141080) · Other

The 20th Annual General Shareholders' Meeting on March 31, 2026, to approve financial statements and appoint a new director (Low importance estimated as standard annual meetings without major corporate changes usually have minimal price impact) scheduled

3/31/2026, 12:00:00 AM

Daewoong Pharmaceutical Co Ltd (069620) · Other

The 25th Annual General Meeting of Shareholders is scheduled for March 26, 2026. Low importance is estimated as the agenda items are routine and unlikely to cause significant price volatility scheduled.

3/26/2026, 12:00:00 AM

Alteogen Inc (196170) · Other

Alteogen's exclusive license agreement with Biogen for its ALT-B4 technology on March 25, 2026, is expected to have a >10% price impact due to the significant deal size of 867.6 billion KRW, scheduled.

3/25/2026, 12:00:00 AM

AprilBio Co Ltd (397030) · Other

The 13th Annual General Meeting of Shareholders was held on March 25, 2026. Resolutions passed included the approval of the 2025 financial statements, amendments to the articles of incorporation, and the granting of stock options.

3/25/2026, 12:00:00 AM

GC Cell Corporation (144510) · Earnings Release

Reported FY2025 results on March 24, 2026, with a significant net loss of KRW 273.5 billion, primarily due to a one-time, non-cash goodwill impairment charge of approximately KRW 220 billion from a past merger. High importance is assigned due to the magnitude of the net loss relative to revenue, which is expected to cause a price impact exceeding 10%.

3/24/2026, 12:00:00 AM